<!DOCTYPE html>
<html lang="en-US">
<meta charset="UTF-8">

<title>OB/GYN Pocket</title>
<meta name="theme-color" content="#000000" />
<meta name="description" content="Orilissa">
<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="manifest" href="manifest.json">
<link rel="stylesheet" href="css/w3.css">
<link rel="stylesheet" href="css/hg.css">


<body onload="SetUpPage()">

    <header id="MyHeader" class="hg-NavBar">
        <a id="bkbtn" class="hg-BackButton" href="javascript:void(0)" onclick="goBack()"></a>
        <a id="hmbrgbtn" class="hg-HamBtn" href="javascript:void(0)" onclick="SideBarOpen()"></a>
        <span id="titbar" class="hg-NavBarTitle"></span>
    </header>

    <nav class="hg-SideBar" id="mySidebar"></nav>

    <div class="hg-OverLay  " onclick="SideBarClose()" title="close side menu" id="myOverlay"></div>

    <div class="hg-Content">

        <main class="hg-InfoContent">
            <h1 class="hg-h1PageTitle">Orilissa (elagolix)</h1>

            <!--Mechanism-->
            <section class="accordian">
                <button onclick="AccToggle('orilissamoa')" class="hg-accBtn">Mechanism of action<span id="orilissamoa_c" class="hg-NavLinkChevron"></span></button>
                <div id="orilissamoa" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Oral GnRH receptor antagonist. <sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <!--Indications-->
            <section class="accordian">
                <button onclick="AccToggle('indiorilissa')" class="hg-accBtn">Indications<span id="indiorilissa_c" class="hg-NavLinkChevron"></span></button>
                <div id="indiorilissa" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Moderate to severe endometriosis pain. <sup>1</sup></li>
                    </ul>
                </div>
            </section>

             <!--Age-->
             <section class="accordian">
                <button onclick="AccToggle('ageorilissa')" class="hg-accBtn">Age<span id="ageorilissa_c" class="hg-NavLinkChevron"></span></button>
                <div id="ageorilissa" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Safety/effectiveness in patients less than 18 years of age have not been established.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <!--Contraception-->
            <section class="accordian">
                <button onclick="AccToggle('contraceporilissa')" class="hg-accBtn">Contraception<span id="contraceporilissa_c" class="hg-NavLinkChevron"></span></button>
                <div id="contraceporilissa" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Estrogen-containing contraceptives are expected to reduce the efficacy.<sup>1</sup></li>
                        <li>Effect of progestin-only contraceptives on the efficacy is unknown.<sup>1</sup></li>
                        <li>Advise use non-hormonal contraceptives during treatment and one week after discontinuing treatment.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <!--Dosage-->
            <section class="accordian">
                <button onclick="AccToggle('doseorilissa')" class="hg-accBtn">Dosage<span id="doseorilissa_c" class="hg-NavLinkChevron"></span></button>
                <div id="doseorilissa" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Dysmenorrhea and non-menstrual pelvic pain:<sup>1</sup>
                            <ul>
                                <li>Orilissa 150 mg QD.</li>
                                <li>Max duration 24 months.</li>
                            </ul>
                        </li>
                        <li>Dysmenorrhea, non-menstrual pelvic pain + dyspareunia:<sup>1</sup>
                            <ul>
                                <li>Orilissa 200 mg BID.</li>
                                <li>Max duration 6 months.</li>
                            </ul>
                        </li>
                        <li>Moderate hepatic impairment (Child-Pugh Clas B):<sup>1</sup>
                            <ul>
                                <li>Orilissa 150 mg QD.</li>
                                <li>Max duration 6 months.</li>
                                <li>Mild hepatic impairment (Child-Pugh Clas A) does not need dose adjustment.</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </section>

            <!--Contraidications-->
            <section class="accordian">
                <button onclick="AccToggle('contraorilissa')" class="hg-accBtn">Contraidications<span id="contraorilissa_c" class="hg-NavLinkChevron"></span></button>
                <div id="contraorilissa" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Pregnancy.<sup>1</sup></li>
                        <li>Known osteoporosis.<sup>1</sup></li>
                        <li>Severe hepatic impairment because of the risk of bone loss.<sup>1</sup></li>
                        <li>Concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil).<sup>1</sup></li>     
                                
                    </ul>
                </div>
            </section>

            <!--Side effects-->
            <section class="accordian">
                    <button onclick="AccToggle('seorilissa')" class="hg-accBtn">Side effects<span id="seorilissa_c" class="hg-NavLinkChevron"></span></button>
                    <div id="seorilissa" class="hg-accDivMain">
                        <ul class=hg-accUl>
                            <li>Most common (>5%) hot flushes, night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions, and mood changes.<sup>1</sup></li>
                            <li>Decrease in menstrual bleeding which may reduce ability to recognize occurrence of pregnancy.<sup>1</sup></li>
                            <li>Bone loss.
                                <ul>
                                    <li>Dose-dependent decrease in bone mineral density which is greater with increasing duration of use and may not be completely reversible after stopping treatment.<sup>1</sup></li>
                                    <li>Impact of decreases in bone mineral density on long-term bone health and future fracture risk is unknown.<sup>1</sup></li>
                                    <li>Consider assessment of bone mineral density in patients with a history of low-trauma fracture or other risk factors for osteoporosis. Do not use in women with known osteoporosis.<sup>1</sup></li>
                                </ul>
                            </li>
                            <li>Suicidal ideation and exacerbation of mood disorders.<sup>1</sup></li>
                            <li>Elevation of serum alanine aminotransferase (ALT) .<sup>1</sup></li>
                        </ul>
                    </div>
                </section>

            <section class="accordian">
                <button onclick="AccToggle('orilissaRefs')" class="hg-accBtn">References:<span id="orilissaRefs_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="orilissaRefs" class="hg-accDivMain">
                    <ol class="hg-accOlRef">
                        <li><a href="https://www.orilissa.com/">Orilissa</a></li>
                    </ol>
                </div>
            </section>


        </main>

        <div class="hg-AddContent">
            <p class="hg-AddSmall ">AD</p>
            <p class="hg-AddLarge  ">AD</p>
        </div>

    </div>

    <script defer src="script.js"></script>
    <script defer src="script-aux.js"></script>

</body>

</html>